Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II multicentre trial of salvage chemotherapywith Gem-TIP for relapsed germ cell cancer.

Trial Profile

Phase I/II multicentre trial of salvage chemotherapywith Gem-TIP for relapsed germ cell cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Chlorphenamine; Cisplatin; Dexamethasone; Filgrastim; Ifosfamide; Lenograstim; Mesna; Paclitaxel; Pegfilgrastim; Ranitidine
  • Indications Germ cell and embryonal neoplasms; Germ cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 Planned end date changed from 31 Aug 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 03 Oct 2012 Accrual to date is 100% according to United Kingdom Clinical Research Network.
    • 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top